The Company celebrates a record 65 storefronts across Florida

Trulieve Cannabis Corp. (CSE: TRUL) ( OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 67th nationwide. The new dispensary will be the Company’s fourth in Hillsborough County and its first in Brandon .


The new dispensary supports Trulieve’s goal of expanding and ensuring direct, reliable patient access to medical cannabis across its home state of Florida . It joins the Company’s 64 other dispensaries statewide, including several in nearby Tampa , St. Petersburg , and Clearwater .

“Acess plays a huge role for us at Trulieve. From our first store to our newest one in Brandon , we’re constantly focused on providing patients with the access they need to the medications they use daily for natural, effective relief,” said Trulieve CEO Kim Rivers . “Opening stores in areas without a dispensary like Brandon is more than being the first, it’s about actively connecting with a community. We’ve developed an incredible relationship with our supportive Truliever family throughout Hillsborough and we’re pleased to continue expanding access to patients in the area for many years to come.”

In honor of the Company’s brand new dispensary, all patients — from those new to Trulieve to the dedicated Truliever community — will be eligible for a 25% in-store discount at the new Brandon dispensary on opening day. In line with policies adopted statewide, all visitors are required to wear masks inside the dispensary. Additionally, only patients and their state-approved caregivers will be allowed inside the waiting room and dispensary at this time.

ANNOUNCING : Trulieve Brandon Opening
WHERE : 638 Oakfield Drive, Brandon, Florida 33511
WHEN : Wednesday, November 4, 2020 , at 9:00 AM

In stores and online, patients will find Florida’s largest selection of THC and CBD products , available in a variety of delivery methods, including edibles, smokable cannabis, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers home delivery statewide for patients and convenient in-store pickup at each of its 65 dispensaries in the state.

To assist patients with ordering, Trulieve has made our entire catalog of products available for online ordering, with in-store pickup or statewide home delivery options available. In addition, patients can schedule a 30-minute complimentary virtual consultation with a Trulieve certified consultant to help navigate questions on products, devices or to review their doctor’s recommendation. To learn more about consultations, click here to read Trulieve’s blog .

Furthermore, to assist with CDC recommendations for social distancing and in compliance with additional company-enforced safety guidelines, several measures have been taken to ensure the health and well-being of employees and patients, including modifying the store layout, installation of plexiglass partitions and HEPA air filtration scrubbers in the dispensaries, increasing access to masks and sanitizer throughout the store for staff and visitors, utilizing visual aids to direct traffic throughout the store, and increasing the frequency of deep cleanings for all dispensaries.

Trulieve is closely monitoring the coronavirus situation and will update store policies as needed to ensure the safety of patients and staff. All updates will be shared directly on Trulieve’s website as they are enacted.

The Office of Medical Marijuana Use recently announced the registry was approaching 440,000 registered medical marijuana patients with an active ID card, with Trulieve consistently selling approximately half of the state’s overall volume per the Florida Department of Health. To support the state’s rapidly growing patient base, there are nearly 2,700 registered ordering physicians in the State of Florida .

For more information, please visit www.Trulieve.com .

About Trulieve
Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also operates in California , Massachusetts , and Connecticut . Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.

To learn more about Trulieve, visit www.Trulieve.com .

Cision View original content: http://www.prnewswire.com/news-releases/trulieve-opens-brandons-first-dispensary-expands-access-for-hillsborough-area-patients-301165863.html

SOURCE Trulieve Cannabis Corp.

News Provided by PR Newswire via QuoteMedia

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less